New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
11:44 EDTESRXExpress Scripts repeats FY14 adjusted EPS view $4.82-$4.94, consensus $4.87
Repeats FY14 adjusted EBITDA view $6.775B-$6.975B. Sees FY14 adjusted EBITDA per adjusted claim $5.20-$5.30. Sees FY14 EPS growth of 17%-20% excluding UNH. Sees FY14 adjusted claims 1.27B-1.33B. Comments from slides that are being presented at the Bank of America Merrill Lynch Healthcare Conference.
News For ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
16:39 EDTESRXBerkshire Hathaway gives quarterly update on stakes
Subscribe for More Information
14:53 EDTESRXCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use